How Pfizer and BioNTech are Moving with Safety and Speed to Develop a Potential COVID-19 Vaccine

Since Pfizer and our collaboration partner, BioNTech, begun our mission to develop a COVID-19 vaccine, safety has been our guiding principle every step of the way. At the same time, given the urgency of the global pandemic, we continue to move at record-breaking speed. We recently started the phase […]

Click here to view original web page at www.pfizer.com

Expediting the development of a potential #COVID19 vaccine is important, with safety at the forefront.

Read how we’re collaborating and marshaling our expertise as we seek to develop a safe, effective and accessible #vaccine:

— Pfizer Inc. (@pfizer) July 27, 2020

UPDATE: $PFE $BNTX mRNA-based #vaccine candidate against SARS-CoV-2 (BNT162b2) is moving into Phase 2/3 clinical development and enrollment.

➡️ Read the release: https://t.co/9PmDiChTCs #COVID19 @BioNTech_Group pic.twitter.com/LQiOVlzlP3

— Pfizer Inc. (@pfizer) July 27, 2020

View this post on Instagram

Our long heritage 📘 Of producing life-changing #vaccines 👩🏽‍🔬 Is built on outstanding #innovation 💡 Not only in #research & development 🧪 But also in #manufacturing 📦 . . Visit pfizer.com to see how we're leveraging this deep knowledge to support the global supply of a potential #COVID19 vaccine. . . #Coronavirus #Pandemic #Outbreak #Vaccines #Science #Manufacturing #Technology #SupplyChain #STEM #EssentialWorkers #PfizerProud

A post shared by Pfizer Inc. (@pfizerinc) on Jul 20, 2020 at 6:51am PDT